Perrigo Co PLC (PRGO)
30.58
+0.09
(+0.30%)
USD |
NYSE |
Apr 24, 13:14
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 4.144B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -13.40% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.8933 |
| Price to Book Value | 0.8692 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.276 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8543 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 78.50% |
Profile
| Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne. |
| URL | https://www.perrigo.com |
| Investor Relations URL | https://investor.perrigo.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 09, 2024 (est.) |
| Last Earnings Release | Feb. 27, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 07, 2024 |
Ratings
Profile
| Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm’s product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne. |
| URL | https://www.perrigo.com |
| Investor Relations URL | https://investor.perrigo.com/ |
| HQ State/Province | N/A |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 09, 2024 (est.) |
| Last Earnings Release | Feb. 27, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 07, 2024 |